Severe Thrombocytopenia in a Patient With Lung Adenocarcinoma Severe Thrombocytopenia in a Patient With Lung Adenocarcinoma
This case of severe grade V thrombocytopenia caused by nivolumab highlights the need for clinicians to be aware of this potential adverse effect of immune-checkpoint inhibitors.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 14, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Lynparza approved in the US as a 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that Lynparza (olaparib) has been approved in the US for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma (pancreatic cancer) (Source: World Pharma News)
Source: World Pharma News - December 31, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

FDA approves olaparib for gBRCAm metastatic pancreatic adenocarcinoma
FDA approved olaparib (LYNPARZA ®, AstraZeneca) for maintenance treatment of patients with gBRCAm metastatic pancreatic adenocarcinoma, as detected by an FDA-approved test, whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 30, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves First PARP Inhibitor as Frontline Maintenance in Pancreatic Cancer
The FDA approved olaparib for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma. (Source: CancerNetwork)
Source: CancerNetwork - December 30, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Lynparza recommended by FDA advisory committee for 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
AstraZeneca and MSD Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 7 to 5 to recommend Lynparza (olaparib) as a 1st-line maintenance monotherapy for patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas (pancreatic cancer), whose disease has not progressed following 1st-line platinum-based chemotherapy. (Source: World Pharma News)
Source: World Pharma News - December 18, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

PET/CT plays role in lung adenocarcinoma management
(American Roentgen Ray Society) According to an article published in the American Journal of Roentgenology (AJR), FDG PET, combined with high-resolution CT, has value for predicting invasive histopathologic subtypes, but there was no significance for predicting invasive growth patterns of early lung adenocarcinoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 16, 2019 Category: International Medicine & Public Health Source Type: news

Chaga Mushroom (Inonotus obliquus) inhibits growth of both lung adenocarcinoma (A549) cells and Aspergillus fumigatus
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - December 11, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Modulation of proliferation factors in lung adenocarcinoma with an analysis of the transcriptional consequences of genomic EGFR activation
(Impact Journals LLC) Molecular subtypes based on copy number, DNA methylation, and mRNA expression had variable proliferation levels, the highest correlating with decreased survival. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2019 Category: International Medicine & Public Health Source Type: news

Virtual biopsy accurately diagnoses pancreatic cysts
A new "virtual biopsy" using ultrasound guidance allows doctors to definitively...Read more on AuntMinnie.comRelated Reading: USPSTF again dismisses pancreatic cancer screening New class of radiotracers targets many cancer types Can radiomics detect pancreatic ductal adenocarcinoma? Optical imaging finds small tumors (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 6, 2019 Category: Radiology Source Type: news

Biocon, Mylan launch cancer drug in US market
Ogivri, available in a 420mg multi-dose vial and a 150mg single-dose vial, will be used for treatment of all types of breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 2, 2019 Category: Pharmaceuticals Source Type: news

CT radiomics predicts lung cancer immunotherapy response
A new radiomics technique can determine which lung cancer patients will benefit...Read more on AuntMinnie.comRelated Reading: AI, radiomics predict prostate cancer aggressiveness CT radiomics uses immunohistology to detect thyroid cancer AI can improve reproducibility of radiomics in CT Can radiomics detect pancreatic ductal adenocarcinoma? AI, radiomics can help predict chemotherapy response (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 26, 2019 Category: Radiology Source Type: news

How a 73-year-old heavy smoker's 'velvety' palms turned out to be a sign of lung cancer
The unnamed woman, of São Paulo, Brazil, had 'tripe palms' - often the sign of an underlying cancer. Tests revealed the woman had adenocarcinoma and she had treatment. (Source: the Mail online | Health)
Source: the Mail online | Health - November 18, 2019 Category: Consumer Health News Source Type: news

Protein could offer therapeutic target for pancreatic cancer
A protein that drives growth of pancreatic cancer, and which could be a target for new treatments, has been identified by researchers at the Crick. The study, published in Nature Cell Biology, looked into the most common type of pancreatic cancer, pancreatic ductal adenocarcinoma. This is an aggressive cancer that develops from secretory and tubular cells of the pancreas. (Source: World Pharma News)
Source: World Pharma News - November 12, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

TAS-102 Prolongs Survival in Metastatic Gastric, GEJ Adenocarcinoma
TAS-102 improved overall survival, compared with placebo, in patients with metastatic gastric or gastroesophageal junction (GEJ) cancer. (Source: CancerNetwork)
Source: CancerNetwork - October 15, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news

Pancreatic Cancer: What the ESPAC-4 Randomized Adjuvant Chemotherapy Trial Tells Us
Researchers examine patterns of recurrence after resection of pancreatic ductal adenocarcinoma.   (Source: CancerNetwork)
Source: CancerNetwork - October 11, 2019 Category: Cancer & Oncology Authors: Leanne Marcello, MS Source Type: news

Prognostic Value of Intraoperative Bile Spillage in Gallbladder Adenocarcinoma
Intraoperative bile spillage might serve as a prognostic tool for gall bladder cancer.   (Source: CancerNetwork)
Source: CancerNetwork - October 3, 2019 Category: Cancer & Oncology Authors: Leanne Marcello, MS Source Type: news

Fungal invasion of pancreas creates cancer risk
Certain fungi move from the gut to the pancreas, expand their population more than a thousand-fold, and encourage pancreatic cancer growth, a new study finds. Published online in Nature October 2, the study is the first to offer strong evidence that the mycobiome - the local mix of fungal species in the pancreas - can trigger changes that turn normal cells into pancreatic ductal adenocarcinoma or PDA. (Source: World Pharma News)
Source: World Pharma News - October 2, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Combination therapy shows promise against fast-growing lung cancer
A trio of genetic pathway inhibiting compounds shrunk lung tumors in mice and human cancer cells caused by a mutation in the KRAS gene, suggesting a new treatment method for adenocarcinomas. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 19, 2019 Category: Consumer Health News Source Type: news

Study finds new way to make chemotherapy more effective against pancreatic cancer
ROCHESTER, Minn. -- Pancreatic adenocarcinoma (PDAC) is a lethal malignancy that most often is resistant to chemotherapy. Researchers have been searching for ways to increase the sensitivity of the tumors to cancer-fighting drugs. A Mayo Clinic-led study published today opens a promising new front in that battle. Using patient cell lines and tumor-bearing models, researchers [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 18, 2019 Category: Databases & Libraries Source Type: news

Can CT-Based Biomarkers Help Guide Pancreatic Cancer Therapy?
An imaging-based biomarker may offer a way to personalize treatment for pancreatic ductal adenocarcinoma. (Source: CancerNetwork)
Source: CancerNetwork - September 9, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

What Are Treatment Options After Progression in PDL-1 –Positive Metastatic Lung Adenocarcinoma after Chemo/IO?
What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1 –positive lung adenocarcinoma with no sensitizing mutations? (Source: CancerNetwork)
Source: CancerNetwork - August 23, 2019 Category: Cancer & Oncology Authors: Yuly A. Remolina-Bonilla, MD, Raul R. Trejo-Rosales, MD, Bruno Saldivar-Oviedo, Alejandro Gabutti, MD, Maria T. Bourlon MD, MS Source Type: news

Can Immunotherapy Play a Role in Pancreatic Ductal Adenocarcinoma?
A combination of  durvalumab and tremelimumab was tested on patients with metastatic pancreatic ductal adenocarcinoma. (Source: CancerNetwork)
Source: CancerNetwork - August 13, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

USPSTF Reaffirms Recs Against Screening for Pancreatic Cancer
TUESDAY, Aug. 6, 2019 -- The U.S. Preventive Services Task Force (USPSTF) recommends against screening for pancreatic adenocarcinoma as the potential benefits do not outweigh the potential harms. These recommendations form the basis of a final... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 6, 2019 Category: Pharmaceuticals Source Type: news

Discovery of distinct lung cancer pathways may lead to more targeted treatments
JACKSONVILLE, Fla. -- Known for its poor prognosis, lung adenocarcinoma is the most common type of lung cancer, responsible for about 4 of 10 diagnoses, according to the National Cancer Institute. Researchers on Mayo Clinic's Florida campus can now distinguish between two pathways where this deadly cancer can develop. They say their discovery could help future patients. [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - August 1, 2019 Category: Databases & Libraries Source Type: news

New Combination Shows Early Promise in Gastric Cancer
Patients responded relatively well to the phase I trial testing a new treatment for several malignancies, including gastric and gastroesophageal junction adenocarcinomas. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer
Stabilization of the MYC oncoprotein by KRAS signaling critically promotes the growth of pancreatic ductal adenocarcinoma (PDAC). Thus, understanding how MYC protein stability is regulated may lead to effective therapies. Here, we used a previously developed, flow cytometry–based assay that screened a library of>800 protein kinase inhibitors and identified compounds that promoted either the stability or degradation of MYC in a KRAS-mutant PDAC cell line. We validated compounds that stabilized or destabilized MYC and then focused on one compound, UNC10112785, that induced the substantial loss of MYC protein in both...
Source: Signal Transduction Knowledge Environment - July 16, 2019 Category: Science Authors: Blake, D. R., Vaseva, A. V., Hodge, R. G., Kline, M. P., Gilbert, T. S. K., Tyagi, V., Huang, D., Whiten, G. C., Larson, J. E., Wang, X., Pearce, K. H., Herring, L. E., Graves, L. M., Frye, S. V., Emanuele, M. J., Cox, A. D., Der, C. J. Tags: STKE Research Articles Source Type: news

Tumor Microenvironment and Pancreatic Cancer Therapy Tumor Microenvironment and Pancreatic Cancer Therapy
Chemoresistance and radioresistance are common in pancreatic ductal adenocarcinoma. Do pharmacologic agents address these challenges?Chinese Clinical Oncology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 28, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology Journal Article Source Type: news

AI can improve reproducibility of radiomics in CT
An artificial intelligence (AI) algorithm may be able to help overcome one...Read more on AuntMinnie.comRelated Reading: 6 ways AI will enhance musculoskeletal imaging Can radiomics detect pancreatic ductal adenocarcinoma? AI, radiomics can help predict chemotherapy response AI may predict lymph node metastasis in gastric cancer AI singles out high-risk prostate cancer on mpMRI (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 24, 2019 Category: Radiology Source Type: news

Peritoneal Carcinomatosis Profiles Highlight Gastric Cancer Targets Peritoneal Carcinomatosis Profiles Highlight Gastric Cancer Targets
Sequencing of whole exome and transcriptome of peritoneal carcinomatosis (PC) in patients with gastric adenocarcinoma (GAC) has given novel insights and opened up new therapeutic opportunities, according to Texas-based researchers.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 22, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

CDx Diagnostics Founder and CSO Shares Company ’s Journey
CDx Diagnostics is on a mission to provide clinicians with tests and tools to preempt cancer through enhanced detection of precancerous cellular changes. The Suffern, NY-based company accomplishes this goal with WATS3, a diagnostic platform that synthesizes computer imaging, artificial intelligence, molecular biology and three-dimensional cytopathology to detect precancerous change earlier and more reliably than prior methods. MD+DI caught up with the company’s founder and CSO to discuss the evolution of the company and where it goes from here. MD+DI: Let’s talk a little bit about CDx D...
Source: MDDI - June 21, 2019 Category: Medical Devices Authors: Omar Ford Tags: IVD Source Type: news

FDA approves Amgen and Allergan's KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin ® (trastuzumab)
Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTITM (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. (Source: World Pharma News)
Source: World Pharma News - June 17, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

FDA Approves Amgen And Allergan's KANJINTI ™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin Third FDA Approval From Amgen's Biosimilars Portfolio THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab):  for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. "...
Source: Amgen News Release - June 14, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Special fibroblasts help pancreatic cancer cells evade immune detection
(Cold Spring Harbor Laboratory) A subpopulation of fibroblasts called apCAFs can interact with the immune system to help pancreatic cancer cells avoid detection. Understanding how they work can be key in developing therapeutics for pancreatic ductal adenocarcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 13, 2019 Category: Cancer & Oncology Source Type: news

Dr. Karen L. Reckamp on Germline Mutations and Onset of Lung Adenocarcinoma in Smokers and Nonsmokers
Cancer Network spoke with Karen L. Reckamp, MD, of  City of Hope, about the link between several gene mutations and lung cancer in smokers vs nonsmokers. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2019 Category: Cancer & Oncology Authors: Karen L. Reckamp, MD Source Type: news

Does Oxaliplatin Improve Survival Over Cisplatin in Advanced Gastric Cancer?
Researchers tested the novel oral fluoropyrimidine derivative S-1 plus oxaliplatin vs S-1 plus cisplatin in patients with diffuse-type or mixed-type advanced gastric adenocarcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2019 Category: Cancer & Oncology Authors: Lauren M. Dembeck Source Type: news

NRG trial suggests total neoadjuvant therapy for locally advanced rectal cancer is safe
(NRG Oncology) Results from the first experimental arm using veliparib as part of total neoadjuvant therapy (induction chemotherapy followed by chemoradiotherapy and surgery; TNT) in patients with locally advanced rectal adenocarcinoma on the NRG Oncology Phase II clinical trial NRG-GI002 were recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 1, 2019 Category: Cancer & Oncology Source Type: news

Case: Sinonasal Adenocarcinoma Secondary to Breast Lesion Case: Sinonasal Adenocarcinoma Secondary to Breast Lesion
This unusual case highlights the differential diagnosis of invasive fungal sinusitis versus metastasis with sinus invasion, which can be difficult to differentiate by radiographic appearance.Applied Radiology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 31, 2019 Category: Allergy & Immunology Tags: Radiology Journal Article Source Type: news

Cancer Consultation Low in Noncurable Pancreatic Adenocarcinoma
Likelihood of cancer - directed therapy higher for first consult with medical, radiation oncology versus surgery (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 28, 2019 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, Radiology, Surgery, Journal, Source Type: news

Cancer Consultation Low in Noncurable Pancreatic Adenocarcinoma
TUESDAY, May 28, 2019 -- Many patients with noncurable pancreatic adenocarcinoma do not have a specialized cancer consultation and most do not receive cancer-directed therapy, according to a study published online May 27 in CMAJ, the journal of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 28, 2019 Category: Pharmaceuticals Source Type: news

Cervical Adenocarcinoma Rates Increased in Some Populations
Increasing and stabilizing incidence trends seen for several subpopulations; declines attenuated in SCC (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 2, 2019 Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Internal Medicine, Nursing, Oncology, Pathology, Journal, Source Type: news

Cervical Adenocarcinoma Rates Increased in Some Populations
THURSDAY, May 2, 2019 -- Many populations have increasing or stabilized incidence trends in cervical adenocarcinoma (AC), according to a study published in the June issue of Preventive Medicine. Farhad Islami, M.D., Ph.D., from the American Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 2, 2019 Category: Pharmaceuticals Source Type: news

Can radiomics detect pancreatic ductal adenocarcinoma?
Radiomics and a machine-learning algorithm can differentiate pancreatic ductal...Read more on AuntMinnie.comRelated Reading: AI, radiomics can help predict chemotherapy response AI may predict lymph node metastasis in gastric cancer AI can predict breast cancer molecular subtypes on MRI Russian AI detects lung cancer on CT in 20 seconds AI reliably characterizes pulmonary nodules on CT (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 25, 2019 Category: Radiology Source Type: news

Gene Signature Linked to Survival After Pancreatic-Cancer Surgery Gene Signature Linked to Survival After Pancreatic-Cancer Surgery
In patients with pancreatic ductal adenocarcinoma (PDAC) presence of two single-nucleotide polymorphisms (SNPs) may help predict surgical outcome, according to European researchers.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 18, 2019 Category: Surgery Tags: Hematology-Oncology News Source Type: news

City of Hope scientists are using combination immunotherapy to treat advanced cancers
(City of Hope) City of Hope physician-scientists recently opened two clinical trials to investigate a combination of cytokines and immunotherapy that may be able to transform nearly-impossible-to-treat cancer into a disease that can be corralled into remission. Daneng Li, M.D., is treating patients with advanced liver (hepatocellular) cancer, while Joseph Chao, M.D., is treating patients with advanced stomach and esophageal cancer (gastric and gastroesophageal junction adenocarcinoma). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 8, 2019 Category: Cancer & Oncology Source Type: news

Neoadjuvant Chemotherapy Key to Survival in Pancreatic Cancer
Three factors independently linked to prolonged survival in BR/LA pancreatic ductal adenocarcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 4, 2019 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Surgery, Journal, Source Type: news

Neoadjuvant Chemotherapy Key to Survival in Pancreatic Cancer
THURSDAY, April 4, 2019 -- Three factors can predict survival in patients with borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC), according to a study published online April 2 in the Annals of Surgery. Mark... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 4, 2019 Category: Pharmaceuticals Source Type: news

Favorable Results Seen With APX005M in Combination Therapy for Metastatic Ductal Pancreatic Adenocarcinoma
Cancer Network spoke with Mark H. O'Hara, MD, about the safety and efficacy of APX005M in combination with standard chemotherapy with or without nivolumab. (Source: CancerNetwork)
Source: CancerNetwork - April 4, 2019 Category: Cancer & Oncology Authors: Mark H. O & #039;Hara, MD Source Type: news

Tumor microenvironment analyzed to increase effectiveness of preclinical trials
(Kazan Federal University) It was shown that co-culturing HeLa adenocarcinoma cells, peripheral blood mononuclear cells, and mesenchymal stromal cells results in changes in the proliferative activity of the peripheral blood mononuclear cells and mesenchymal stromal cell populations. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 2, 2019 Category: Cancer & Oncology Source Type: news

Radiomic Features May Predict Response to Chemo in NSCLC
TUESDAY, March 26, 2019 -- For patients with lung adenocarcinoma, radiomic texture features extracted from within and around the nodule on baseline computed tomography (CT) scans can predict response to chemotherapy, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 26, 2019 Category: Pharmaceuticals Source Type: news

Car accident with airbag deployment trauma showed special pattern in bone scan - Chuang TL, Hsu TW, Chou SC, Wang YF.
A 72-year-old man had rectal adenocarcinoma with partial obstruction with liver and lung metastases. Bone scan showed special pattern with bony destructions to the lateral aspect of the left first to fourth and right first to 10th ribs (in a row in continu... (Source: SafetyLit)
Source: SafetyLit - March 24, 2019 Category: International Medicine & Public Health Tags: Engineering, Physics, Structural Soundness and Failure Source Type: news